Table 2.
Five-year survival rates of the 730 NPC patients
| All (N = 730) |
Nimotuzumab Arm (N = 184) |
No Nimotuzumab Arm (N = 546) |
Chi-square | P value | |
|---|---|---|---|---|---|
| DMFS | 87.49% | 93.09% | 85.61% | 6.343 | 0.012 |
| III | 89.81% | 94.59% | 88.22% | ||
| IV | 83.43% | 90.56% | 80.93% | ||
| LRRFS | 88.60% | 85.34% | 89.79% | 2.012 | 0.156 |
| III | 90.16% | 87.22% | 91.21% | ||
| IV | 85.71% | 82.00% | 87.17% | ||
| PFS | 78.47% | 79.96% | 77.99% | 2.459 | 0.117 |
| III | 78.72% | 81.27% | 77.88% | ||
| IV | 63.15% | 70.90% | 60.52% | ||
| OS | 80.96% | 88.91% | 78.30% | 7.565 | 0.006 |
| III | 88.53% | 96.33% | 85.97% | ||
| IV | 67.69% | 76.24% | 64.79% |
OS overall survival, DMFS distant metastasis–free survival, LRRFS locoregional relapse–free survival, and PFS progression-free survival